论文部分内容阅读
观察了48例初发性急性髓性白血病(denovo AML)患者发病及完全缓解时,细胞形态学上骨髓三系成熟血细胞中呈病态造血改变(TMDS)的细胞比率,并作了免疫组织化学染色和流式细胞仪的分析研究,参照经修订的Brito-Babapulle等TMDS诊断标准,分为有TMDS(AML/TMDs)组及非AML/TMDS组。采用日本成人白血病研究组(JALSG)AML-87或89方案进行诱导-巩固和维持治疗。对TMDS组与非TMDS组的临床表现、生存期和CR期作了比较研究。 结果 12例(25％)初发性AML有TMDS,包括
Observed 48 cases of patients with primary acute myeloid leukemia (denovo AML) in the pathogenesis and complete remission, the cell morphology of bone marrow in the third line of mature blood cells showed pathological hematopoiesis (TMDS) cell ratio, and made immunohistochemical staining The analysis of flow cytometry and the TMDS diagnostic criteria such as the revised Brito-Babapulle were divided into TMDS (AML/TMDs) and non-AML/TMDS groups. Induction-consolidation and maintenance therapy was performed using the Japanese Adult Leukemia Group (JALSG) AML-87 or 89 regimen. A comparative study was conducted on the clinical manifestations, survival periods, and CR phases in TMDS and non-TMDS groups. Results Twelve cases (25%) of primary AML had TMDS, including